FindTrial
Sign In

Effect of type iii interferon gene polymorphism on CMV/EBV infection and antiviral efficacy in patients with renal transplantation

Effect of type iii interferon gene polymorphism on CMV/EBV infection and antiviral efficacy in patients with renal transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060232
Enrollment
Unknown
Registered
2022-05-22
Start date
2022-05-13
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral infection

Interventions

According to the test results, they were divided into two groups:Antiviral therapy was performed after positive EBV/CMV test

Sponsors

The Second Affiliated Hospital of Hainan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.All transplant recipients were evaluated before surgery.HLA typing was based on the international standard of HLA six-antigen mismatch. PRA and preoperative lymphotoxicity tests were negative; 2.Volunteer and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. EBV/CMV current infection (virus DNA detection); 2. Positive anti HLA antibody; 3. Have a history of blood transfusion and pregnancy within 3 months before surgery; 4. Participate in other studies at the same time.

Design outcomes

Primary

MeasureTime frame
Polymorphism of type ? interferon gene;CMV/EBV virus nucleic acid content;—

Countries

China

Contacts

Public ContactHua Pei

The Second Affiliated Hospital of Hainan Medical University

phzmh61@aliyun.com+86 13637648754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026